Keros Therapeutics
KROS
104 hedge funds and large institutions have $433M invested in Keros Therapeutics in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 43 increasing their positions, 20 reducing their positions, and 21 closing their positions.
115% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 20
3.77% more ownership
Funds ownership: 68.44% → 72.22% (+3.8%)
5% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 21
2% less funds holding
Funds holding: 106 → 104 (-2)
52% less capital invested
Capital invested by funds: $893M → $433M (-$460M)
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$26M |
| 2 |
Citigroup
New York
|
+$19.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$13.5M |
| 4 |
Alkeon Capital Management
New York
|
+$11.8M |
| 5 |
Renaissance Technologies
New York
|
+$5.98M |
Top Sellers
KROS Hedge Fund Activity: Q2 2022 in Review
104 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q2 2022, worth a combined $433M — down 52% from $893M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of KROS and 20 opened new positions — a net loss of 1 holder — while 20 trimmed existing stakes and 43 added.
The largest buyer was Fidelity Investments, adding an estimated $26M. The largest seller was Deep Track Capital, cutting an estimated $28.1M.
- 104 institutional investors held Keros Therapeutics (KROS) as of Q2 2022, down from 106 in Q1 2022.
- Funds reported $433M of Keros Therapeutics stock for Q2 2022, down 52% quarter-over-quarter.
- 20 funds opened new Keros Therapeutics positions in Q2 2022 and 21 closed out, a net change of -1 holder.
- The largest Keros Therapeutics buyer in Q2 2022 was Fidelity Investments, an estimated $26M added.
- The largest Keros Therapeutics seller in Q2 2022 was Deep Track Capital, an estimated $28.1M sold.
Based on aggregated 13F filings for Q2 2022.